Skyhawk Therapeutics Says to Work With Merck to Develop Drug Candidates

Date : 07/08/2019 @ 12:29PM
Source : Dow Jones News
Stock : Merck and Co Inc (MRK)
Quote : 89.865  -0.105 (-0.12%) @ 7:44PM

Skyhawk Therapeutics Says to Work With Merck to Develop Drug Candidates

Merck (NYSE:MRK)
Historical Stock Chart

1 Year : From Jan 2019 to Jan 2020

Click Here for more Merck Charts.

By Michael Dabaie


Skyhawk Therapeutics Inc. said it is in a strategic collaboration with Merck & Co. (MRK).

The company said it is collaborating with Merck, which is known as MSD outside the U.S. and Canada, on small molecules that modulate RNA splicing for the potential treatment of certain neurological diseases and cancer.

Skyhawk said it is eligible to receive about $600 million per program target consisting of an upfront cash payment and, if Merck exercises its option, potential opt-in fees, milestone payments, as well as royalties on sales of commercialized products.

Skyhawk will grant Merck the option to exclusively license worldwide intellectual property rights to candidates discovered and developed under the collaboration that are directed to program targets.


Write to Michael Dabaie at


(END) Dow Jones Newswires

July 08, 2019 08:14 ET (12:14 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest MRK Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.